Autonomix Medical, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
AMIX Nasdaq 3840 autonomix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Autonomix Medical, Inc.

Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025 - Jan 17th, 2025 1:00 pm
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series - Jan 15th, 2025 1:30 pm
Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting - Jan 13th, 2025 1:30 pm
Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology - Dec 30th, 2024 1:30 pm
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment - Dec 23rd, 2024 1:30 pm
Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality - Dec 19th, 2024 1:30 pm
Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025 - Dec 5th, 2024 1:30 pm
Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option - Nov 25th, 2024 9:00 pm
Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering - Nov 22nd, 2024 2:15 pm
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update - Nov 11th, 2024 1:00 pm
Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction - Oct 31st, 2024 12:00 pm
Autonomix Medical, Inc.’s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial - Oct 30th, 2024 12:30 pm
Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial - Oct 28th, 2024 12:00 pm
Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th - Oct 25th, 2024 3:30 pm
Autonomix Announces Reverse Stock Split - Oct 22nd, 2024 12:30 pm
Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC - Oct 8th, 2024 12:30 pm
This Company Is Taking An Innovative, Non-Opioid Approach To Pain Management For Pancreatic Cancer - Oct 3rd, 2024 1:40 pm
Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum - Sep 20th, 2024 12:30 pm
Autonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain Patients - Sep 9th, 2024 11:00 am
Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference - Aug 27th, 2024 12:30 pm